Dr. Farran Abat

00:00 – Introduction

• Dr. Barrett introduces Dr. Farran Abat, an orthopedic surgeon and traumatologist from Barcelona specializing in sports medicine
• They first met at a podiatry congress in the Canary Islands, where Dr. Abat presented on the convergence of tendinopathy and neuropathy
• Dr. Barrett previews the key insight: chronically degenerating tendons can become centrally sensitized, producing a “phantom-type” nerve pain that persists even after structural healing

01:18 – Dr. Abat’s Background & Clinical Setting

• He trained under a tendinopathy pioneer
• Director of Resport Clinic, one of the three largest sports medicine clinics in Catalonia
• High-volume practice with a large population of tendinopathy patients, predominantly athletes

02:05 – Tendinopathy Meets Neuropathy: The Central Framework

• Dr. Abat explains that in chronic tendinopathy (tendinosis), the body attempts repeated healing cycles but fails to fully resolve the condition
• In this chronic state, nerves and new blood vessels infiltrate the tendon tissue — a neuropathological process well-documented in anatomic and histological studies
• Citing work by Professor Jill Cook, he introduces central sensitization: even after structural tendon improvement, the nervous system can remain in a pain-amplified state
• Key clinical implication: patients may have a nearly normal ultrasound appearance yet still experience burning, twitching tendon pain — the “pain is no longer in the tendon, it’s in the nerves”

05:24 – Tendinitis vs. Tendinopathy: Setting the Record Straight

• Dr. Barrett clarifies the distinction for the audience:
  • Tendinitis = acute, inflammation-driven
  • Tendinopathy / Tendinosis = degenerative, chronic, not truly inflammatory
• Draws the parallel to plantar fasciitis vs. plantar fasciopathy — the same degenerative reality, just with outdated terminology that has stuck culturally
• The chronic degenerative process involves failed healing, nerve in-growth, and vascular proliferation — not sustained acute inflammation

07:19 – The Centrally Sensitized Tendon: Clinical Picture

• “Good ultrasound, bad pain” patients: tendon appears structurally improved but neuropathic pain persists
• This is attributable to nociceptive sensitization — pain signals from the tendon’s nerve supply that have been transmitted to the brain for so long they persist independently
• Analogy drawn to phantom limb pain
• Clinical takeaway: treat early — the longer the chronic state persists, the more entrenched the central sensitization becomes

08:03 – Biomechanics: The Non-Negotiable Foundation

• Dr. Barrett raises the importance of biomechanical correction as the essential underpinning of tendinopathy treatment
• “You can put the fire out all day, but if someone keeps throwing gas on it…”
• Without correcting biomechanics, regenerative treatments yield only temporary benefit — the tendon will re-injure

08:54 – Dr. Abat’s Treatment Philosophy: The Full Picture

• Dr. Abat describes a university joke with students: if you treat the tendon in isolation with electrolysis + PRP + exercise and skip biomechanics, you’ll “have a patient for life”
• Biomechanics are responsible for ~80% of the root cause in most chronic tendinopathy patients
• Treatment must integrate biomechanical correction during the healing process — not sequentially after it
• Podiatric collaboration is an active part of the treatment timeline, including for patients returning to running during recovery
• With this comprehensive approach, >90% of patients avoid surgery

11:32 – Achilles Tendinopathy & Equinus Deformity

• Dr. Barrett shares clinical experience: most Achilles tendinopathy in his practice correlates with an equinus deformity (limited ankle dorsiflexion), driving compensatory pronation and a cascade of downstream pathology
• Raises the question of surgical correction (e.g., gastrocnemius recession) vs. conservative care when the equinus is severe
• Dr. Abat’s approach: conservative first — structured rehab with biofeedback-assisted exercise, early podiatric orthotics, and biomechanical correction during (not after) treatment leads to excellent outcomes in the vast majority of cases

14:59 – Visual Slide Demonstration: Nerve In-Growth in Tendinopathy

• Dr. Abat shares screen and walks through histologic imaging of the Achilles tendon
• Demonstrates nerve fibers (highlighted in yellow) invading the tendon alongside new vasculature
• Activation of tenocytes produces neuroinflammatory signaling → substance P release → persistent pain
• This neuropathic component is not originating inside the tendon proper — it is a nerve-of-the-tendon problem, analogous to a “source of nerve entrapment”

18:55 – Electrolysis as a Therapeutic Tool

• Dr. Barrett raises electrolysis (EPTE® / percutaneous needle electrolysis), noting it is widely used in Spain but underutilized in the United States
• Questions whether the mechanism is primarily regenerative (inflammatory restart) or denervative (ablating the invading nerves)
• Dr. Abat explains: electrolysis uses a 0.3mm ultrasound-guided needle introduced directly into the lesion zone
• Galvanic current dissociates water and salt molecules → induces a localized acute inflammatory response, converting the chronic-phase tendon back to an acute-healing phase
• This is the key to making subsequent regenerative treatments (PRP, stem cells) far more effective — platelets work better in an already-inflamed environment
• The current also acts as a neuromodulatory stimulus: transient pain relief from galvanic effect on nerves creates a therapeutic window for mechanical loading and tissue remodeling

22:51 – The Inflammation Paradox in Chronic Tendon Disease

• Dr. Barrett references the landmark 2003 Harvey Lamont histology study: 50 plantar fasciectomy specimens — zero specimens showed classic inflammatory histology
• This confirmed the degenerative (not inflammatory) nature of chronic plantar fasciopathy and helped shift the paradigm
• Both physicians agree: electrolysis + PRP/stem cells is a synergistic protocol — electrolysis restarts biology; regenerative agents then have a primed environment to work in

25:32 – PRP, Stem Cells & Emerging Biologics

• Current regenerative toolkit at Resport Clinic: leukocyte-rich or leukocyte-poor PRP (custom protocol), mesenchymal stem cells, and intraosseous PRP for bone marrow edema adjacent to tendon insertions
• Dr. Barrett briefly raises BPC-157 and peptides — Dr. Abat notes these are under investigation in Spain but not yet standard of practice there

26:54 – The Problem with Symptom-Only Treatment

• Both physicians lament the culture of symptomatic care: cortisone injections, painkillers, and isolated interventions that ignore root cause
• “We are not correcting the problem” — cortisone provides temporary relief while potentially accelerating long-term tendon destruction

30:50 – The Cortisone Problem: Intraoperative Evidence

• Dr. Abat describes the appearance of tendon tissue during surgery in patients who received prior cortisone injections: areas of necrosis (“death areas”) within otherwise healthy, white, pearlescent tendon
• Cortisone is highly tenotoxic — those affected zones will eventually fail
• Dr. Barrett corroborates with intraoperative findings of calcification and chalky deposits (like “tiny pieces of cottage cheese”) persisting years after a steroid injection

32:34 – Tendinopathy Prevalence: Top Pathologies

• Achilles tendinopathy: #1 in the lower extremity by volume
• Plantar fasciopathy: extremely common in Spain’s large running, CrossFit, and paddle (racket sport) population
• Peroneal tendinopathy: top 3 in lower extremity

33:02 – Tendon Injury Prevention

• Prevention is challenging in recreational athletes who resist prehabilitation and warm-up protocols
• Key principle: “Train to run — don’t run to train”
• 20–30 minutes of structured warm-up exercises pre-activity is evidence-supported but rarely followed without professional supervision
• Eccentric loading protocols (e.g., slow isokinetic holds) are effective but require proper guidance

34:43 – PRP: The Sophistication Gap

• Dr. Barrett recalls being among the first in the U.S. (circa 2000–2001) to use PRP for plantar fasciitis, inspired by a whole-blood injection study for lateral epicondylitis
• Current landscape: PRP concentration, leukocyte content, and delivery method vary enormously across providers — making outcome comparisons nearly impossible
• Dr. Abat’s clinic is running an international study using cellular characterization machines to analyze the exact cellular composition of each patient’s PRP

37:52 – The Future of PRP: Personalized Biologic Therapy

• Vision: individualized PRP formulations tailored to the specific lesion type AND the individual patient’s biologic profile
• Males and females differ in healing response — PRP composition should reflect that
• Concentration (2x vs. 10–12x), leukocyte content, and adjuvant medications added to PRP should all be patient- and lesion-specific
• “There is not only one PRP for everything”

40:57 – Lesion-Specific Considerations

• Tendons with synovial sheaths (e.g., long head of biceps) behave differently from those without
• Plantar fascia with adjacent nerve involvement (tarsal tunnel, medial calcaneal nerve) requires specific caution — aggressive injection in that environment can worsen neuropathic pain
• Diagnosis must be precise and selective before any regenerative treatment is deployed

43:44 – What’s Coming: The Future of Sports Medicine

• Artificial Intelligence: Dr. Abat predicts AI will change diagnostic methodology in the near term — potentially months, not years
• Stem cells and gene therapy: the ability to modify the genetic landscape of healing — “we will be able to change the genetic field of our patients” — is the next frontier

44:47 – Closing Remarks

• Dr. Barrett thanks Dr. Abat for a remarkable conversation and for his presentation in the Canary Islands
• Expressed enthusiasm for connecting cutting-edge European sports medicine with the Pod of Inquiry audience

Special Offer: Save 15% Using Code “SBPOD” At Checkout

Special Offer: Save 15% Using Code “SBPOD” At Checkout